Executives On The Move: Development Hires At BiomX And CytomX, Revance Chooses a CEO
• By Regina Paleski
Two new chief development officers: former Teva Pharma exec moves to microbiome-based therapeutics firm BiomX; and BioGene CMO makes a change to oncology biopharma CytomX. At Revance Therapeutics, a developer of therapeutic neuromodulators, a CEO is chosen.
Recent moves in the industry include changes at the top at iOnctura
and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.
Recent moves in the industry include changes at the top at Mitsubishi Tanabe Pharma and MC2 Therapeutics, plus MindMed acquires chief financial officer from Longboard Pharma.
Recent moves in the industry include new C-suite hires at Janux Therapeutics, BlueSphere Bio and Hansa Biopharma, plus Syndax Pharmaceuticals gets new chief medical officer from Bristol Myers Squibb.
In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.
Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.
Recent moves in the industry include changes at the top at iOnctura
and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.